Header Logo

Connection

CHRISTIE BALLANTYNE to Metabolic Syndrome

Back to Details
This is a "connection" page, showing publications CHRISTIE BALLANTYNE has written about Metabolic Syndrome.
CHRISTIE BALLANTYNE
Connection Strength
3.883
Metabolic Syndrome
  1. Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials. Atherosclerosis. 2023 08; 378:117182.
    View in: PubMed
    Score: 0.627
  2. Postprandial Monocyte Activation in Individuals With Metabolic Syndrome. J Clin Endocrinol Metab. 2016 11; 101(11):4195-4204.
    View in: PubMed
    Score: 0.391
  3. Prevalence of metabolic syndrome and associated risk factors in Asian Indians. J Immigr Minor Health. 2008 Aug; 10(4):313-23.
    View in: PubMed
    Score: 0.223
  4. Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends? Crit Pathw Cardiol. 2007 Jun; 6(2):41-5.
    View in: PubMed
    Score: 0.206
  5. Adipokines and Transitions in Metabolic Health Over Time: The Atherosclerosis Risk In Communities (ARIC) Study. J Clin Endocrinol Metab. 2025 Aug 07; 110(9):e2939-e2945.
    View in: PubMed
    Score: 0.181
  6. Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. Clin Chem. 2005 Jul; 51(7):1102-9.
    View in: PubMed
    Score: 0.180
  7. Prevalence of coronary heart disease and carotid arterial thickening in patients with the metabolic syndrome (The ARIC Study). Am J Cardiol. 2004 Nov 15; 94(10):1249-54.
    View in: PubMed
    Score: 0.173
  8. Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obes Metab. 2004 Sep; 6(5):353-62.
    View in: PubMed
    Score: 0.170
  9. Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab. 2004 Jun; 89(6):2697-703.
    View in: PubMed
    Score: 0.167
  10. Efficacy of rosuvastatin 10 mg in patients with the metabolic syndrome. Am J Cardiol. 2003 Mar 06; 91(5A):25C-27C; discussion 28C.
    View in: PubMed
    Score: 0.153
  11. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab. 2002 Nov; 4(6):407-14.
    View in: PubMed
    Score: 0.150
  12. Evaluation of the efficacy, safety and glycaemic effects of evolocumab (AMG 145) in hypercholesterolaemic patients stratified by glycaemic status and metabolic syndrome. Diabetes Obes Metab. 2017 01; 19(1):98-107.
    View in: PubMed
    Score: 0.098
  13. Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids Health Dis. 2015 Sep 04; 14:103.
    View in: PubMed
    Score: 0.091
  14. Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome. Metab Syndr Relat Disord. 2015 Aug; 13(6):239-47.
    View in: PubMed
    Score: 0.089
  15. The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individuals. J Obes. 2013; 2013:729515.
    View in: PubMed
    Score: 0.081
  16. Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndrome. J Clin Lipidol. 2013 Nov-Dec; 7(6):661-70.
    View in: PubMed
    Score: 0.078
  17. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. J Clin Lipidol. 2013 Jul-Aug; 7(4):292-303.
    View in: PubMed
    Score: 0.077
  18. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study. Eur J Prev Cardiol. 2014 Jul; 21(7):866-75.
    View in: PubMed
    Score: 0.075
  19. Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. Atherosclerosis. 2012 Jun; 222(2):551-6.
    View in: PubMed
    Score: 0.072
  20. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol. 2011 Nov-Dec; 5(6):474-82.
    View in: PubMed
    Score: 0.068
  21. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009 Dec; 7(6):601-10.
    View in: PubMed
    Score: 0.061
  22. CD11c expression in adipose tissue and blood and its role in diet-induced obesity. Arterioscler Thromb Vasc Biol. 2010 Feb; 30(2):186-92.
    View in: PubMed
    Score: 0.061
  23. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol. 2009 Jun 15; 103(12):1694-702.
    View in: PubMed
    Score: 0.059
  24. Platelet reactivity and response to aspirin in subjects with the metabolic syndrome. Am Heart J. 2008 Nov; 156(5):1002.e1-1002.e7.
    View in: PubMed
    Score: 0.057
  25. Association of lactate with blood pressure before and after rapid weight loss. Am J Hypertens. 2008 Dec; 21(12):1337-42.
    View in: PubMed
    Score: 0.056
  26. Eotaxin and obesity. J Clin Endocrinol Metab. 2006 Jan; 91(1):256-61.
    View in: PubMed
    Score: 0.046
  27. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005 Dec; 26(24):2664-72.
    View in: PubMed
    Score: 0.046
  28. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005 Feb; 28(2):385-90.
    View in: PubMed
    Score: 0.044
  29. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clin Ther. 2003 Jun; 25(6):1670-86.
    View in: PubMed
    Score: 0.039
  30. Association of body mass index and waist circumference with subclinical atherosclerosis in retired NFL players. South Med J. 2014 Oct; 107(10):633-9.
    View in: PubMed
    Score: 0.021
  31. Low-density lipoprotein electronegativity is a novel cardiometabolic risk factor. PLoS One. 2014; 9(9):e107340.
    View in: PubMed
    Score: 0.021
  32. Association between lipoprotein associated phospholipase A2 mass and subclinical coronary and carotid atherosclerosis in Retired National Football League players. Atherosclerosis. 2014 Oct; 236(2):251-6.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.